INTERNATIONAL JOURNAL OF SCIENTIFIC DEVELOPMENT AND RESEARCH International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2455-2631 | Impact factor: 8.15 | ESTD Year: 2016
open access , Peer-reviewed, and Refereed Journals, Impact factor 8.15
In -Vitro Study of Favipiravir Marketed 200 mg Tablets
Authors Name:
Navdeep kaur
Unique Id:
IJSDR2209075
Published In:
Volume 7 Issue 9, September-2022
Abstract:
The aim of work to evaluate the marketed tablets of favipiravir of Glenmark which is used for the treatment of covid-19 infection. Dose also varies according to company and firstly designed 200mg favipiravir for the treatment of influenza infection in Japan. Favipiravir is a modified pyrazine analogue and repurposed drug that targets RNA polymerase enzymes. At present, only the oral route is available in the form of tablets in higher doses. They were evaluated in the current studies, i.e., in-vitro drug release studies
"In -Vitro Study of Favipiravir Marketed 200 mg Tablets", International Journal of Science & Engineering Development Research (www.ijsdr.org), ISSN:2455-2631, Vol.7, Issue 9, page no.446 - 448, September-2022, Available :http://www.ijsdr.org/papers/IJSDR2209075.pdf
Downloads:
000337070
Publication Details:
Published Paper ID: IJSDR2209075
Registration ID:201643
Published In: Volume 7 Issue 9, September-2022
DOI (Digital Object Identifier): http://doi.one/10.1729/Journal.31721
Page No: 446 - 448
Publisher: IJSDR | www.ijsdr.org
ISSN Number: 2455-2631
Facebook Twitter Instagram LinkedIn